Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 10/20 | 0.66 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.64 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.64 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
| ▸ | PPARD | Q03181 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | ACLY | P53396 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418801 | 0.86 | SERPINE1 (0.52) | SERPINE1KCNK2KCNK10PPARGPPARD | |
| SCHEMBL19554129 | 0.84 | SERPINE1 (0.66) | SERPINE1KCNK2KCNK10AKR1C4AKR1C3 | |
| SCHEMBL1534369 | 0.82 | RXFP1 (0.68) | KCNK2KCNK10ACLY | |
| SCHEMBL29293869 | 0.81 | KCNK2 (0.58) | SERPINE1KCNK2KCNK10AKR1C4AKR1C3 | |
| SCHEMBL28734377 | 0.81 | KCNMA1 (0.63) | CYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL29721833 | 0.81 | KCNMA1 (0.63) | CYP1A2CYP2D6CYP2C19RAB9A | |
| SCHEMBL1308660 | 0.81 | TMPRSS4 (0.64) | SERPINE1KCNK2KCNK10AKR1C4AKR1C3 | |
| SCHEMBL13802479 | 0.80 | KCNK2 (0.61) | SERPINE1KCNK2KCNK10AKR1C4AKR1C3 | |
| SCHEMBL6351321 | 0.80 | SERPINE1 (0.89) | SERPINE1KCNK2KCNK10AKR1C4AKR1C3 | |
| SCHEMBL420142 | 0.80 | SERPINE1 (1.00) | SERPINE1KCNK2KCNK10AKR1C4AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| EP-2990057-B1 | PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT | RENASCIENCE CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-10092537-B2 | Use for PAI-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2018-10-09 | — | — | US | disclosed |
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-2990057-A1 | NOVEL USE FOR PAI-1 INHIBITOR | Renascience Co., Ltd. (JP) | 2016-03-02 | — | — | EP | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158188-A1 | NOVEL USE FOR PAI-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885KCNK2 4224/4885KCNK10 4092/4885 |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885KCNK2 4007/4885KCNK10 3475/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885KCNK2 4007/4885KCNK10 3475/4885 |
| US-10092537-B2 | Use for PAI-1 inhibitor | SERPINE1, SERPINC1, SERPINB1 | SERPINE1 1/4885KCNK2 4342/4885KCNK10 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.